For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use
LL-37 is the only cathelicidin produced by the human genome, derived from the precursor protein hCAP18. It is a front-line innate immune peptide deficient in chronic wounds (venous leg ulcers, diabetic foot ulcers) but present in normal acute wounds. Two Phase 2 RCTs (n=34 and n=144) established topical LL-37 as safe and wound-healing efficacious, with the clearest benefit in large ulcers (10 cm2 or larger). No Phase 3 data exist. Published preclinical evidence documents pro-tumorigenic activity in ovarian, lung, breast, prostate, and melanoma contexts, and a role as a T-cell autoantigen in psoriasis and SLE, constituting mandatory safety disclosures for any research context.
The complete LL-37 profile includes all use cases with full evidence reviews, mechanism of action deep dive, safety analysis, evidence table, dosing guidance, and stack compatibility data.
For research and educational purposes only · Not medical advice · Consult a qualified physician before any human use